140 related articles for article (PubMed ID: 38632132)
21. Effect of Prophylactic Extended-Infusion Carboplatin on Incidence of Hypersensitivity Reactions in Patients with Ovarian, Fallopian Tube, or Peritoneal Carcinomas.
Pasternak AL; Link NA; Richardson CM; Rose PG
Pharmacotherapy; 2016 Jul; 36(7):723-30. PubMed ID: 27196693
[TBL] [Abstract][Full Text] [Related]
22. Universal tolerance of nab-paclitaxel for gynecologic malignancies in patients with prior taxane hypersensitivity reactions.
Maurer K; Michener C; Mahdi H; Rose PG
J Gynecol Oncol; 2017 Jul; 28(4):e38. PubMed ID: 28541630
[TBL] [Abstract][Full Text] [Related]
23. Dose reduction of steroid premedication for paclitaxel: no increase of hypersensitivity reactions.
Köppler H; Heymanns J; Weide R
Onkologie; 2001 Jun; 24(3):283-5. PubMed ID: 11455223
[TBL] [Abstract][Full Text] [Related]
24. Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions.
Yamada Y; Shirao K; Ohtsu A; Boku N; Hyodo I; Saitoh H; Miyata Y; Taguchi T
Ann Oncol; 2001 Aug; 12(8):1133-7. PubMed ID: 11583196
[TBL] [Abstract][Full Text] [Related]
25. Retrospective evaluation of a rechallenge protocol in patients experiencing hypersensitivity reactions with prior chemotherapy in a tertiary hospital.
Wu HL
J Oncol Pharm Pract; 2019 Sep; 25(6):1388-1395. PubMed ID: 30176784
[TBL] [Abstract][Full Text] [Related]
26. Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.
Berger MJ; Dunlea LJ; Rettig AE; Lustberg MB; Phillips GS; Shapiro CL
Support Care Cancer; 2012 Sep; 20(9):1991-7. PubMed ID: 22089428
[TBL] [Abstract][Full Text] [Related]
27. Hypersensitivity reactions to paclitaxel: The Mexican experience of rapid desensitization.
González RVV; Díaz SNG; Cruz RAC; Gutiérrez OV; Quezada CEL
J Oncol Pharm Pract; 2022 Apr; 28(3):598-604. PubMed ID: 33847195
[TBL] [Abstract][Full Text] [Related]
28. Successful desensitization to docetaxel after severe hypersensitivity reactions in two patients.
Reeves DJ; Callahan MJ; Sutton GP
Am J Health Syst Pharm; 2012 Mar; 69(6):499-503. PubMed ID: 22382481
[TBL] [Abstract][Full Text] [Related]
29. Oral premedication for the prevention of hypersensitivity reactions to paclitaxel.
Zidan J; Hussein O; Abzah A; Tamam S; Farraj Z; Friedman E
Med Oncol; 2008; 25(3):274-8. PubMed ID: 18363113
[TBL] [Abstract][Full Text] [Related]
30. Abraxane for the treatment of gynecologic cancer patients with severe hypersensitivity reactions to paclitaxel.
Fader AN; Rose PG
Int J Gynecol Cancer; 2009 Oct; 19(7):1281-3. PubMed ID: 19820391
[TBL] [Abstract][Full Text] [Related]
31. Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity.
Rose PG; Fusco N; Smrekar M; Mossbruger K; Rodriguez M
Gynecol Oncol; 2003 Jun; 89(3):429-33. PubMed ID: 12798707
[TBL] [Abstract][Full Text] [Related]
32. Intravenous versus oral dexamethasone premedication in preventing Paclitaxel infusion hypersensitivity reactions in gynecological malignancies.
O'Cathail SM; Shaboodien R; Mahmoud S; Carty K; O'Sullivan P; Blagden S; Gabra H; Whear S; Kwon JS; Agarwal R
Int J Gynecol Cancer; 2013 Sep; 23(7):1318-25. PubMed ID: 23907557
[TBL] [Abstract][Full Text] [Related]
33. Retreatment with nedaplatin in patients with recurrent gynecological cancer after the development of hypersensitivity reaction to carboplatin.
Arimoto T; Oda K; Nakagawa S; Kawana K; Tsukazaki T; Adachi K; Matsumoto Y; Yano T; Kozuma S; Taketani Y
J Obstet Gynaecol Res; 2013 Jan; 39(1):336-40. PubMed ID: 22690725
[TBL] [Abstract][Full Text] [Related]
34. Platinum desensitization in patients with carboplatin hypersensitivity: A single-institution retrospective study.
Altwerger G; Gressel GM; English DP; Nelson WK; Carusillo N; Silasi DA; Azodi M; Santin A; Schwartz PE; Ratner ES
Gynecol Oncol; 2017 Jan; 144(1):77-82. PubMed ID: 27789084
[TBL] [Abstract][Full Text] [Related]
35. Cetirizine versus diphenhydramine in the prevention of chemotherapy-related hypersensitivity reactions.
Durham CG; Thotakura D; Sager L; Foster J; Herrington JD
J Oncol Pharm Pract; 2019 Sep; 25(6):1396-1401. PubMed ID: 30419768
[TBL] [Abstract][Full Text] [Related]
36. Impact of institutional interventions on the rate of paclitaxel hypersensitivity reactions.
Jao ME; Indorf AL; Segal EM; Miske A; Eaton KD; Marsolini T; Ghuman S
J Oncol Pharm Pract; 2024 Jan; 30(1):105-111. PubMed ID: 37021579
[TBL] [Abstract][Full Text] [Related]
37. Retrospective evaluation of weekly paclitaxel hypersensitivity reactions reported utilizing an electronic medical record system at a tertiary cancer center.
Lal LS; Gerber DL; Lau J; Dana W
Support Care Cancer; 2009 Oct; 17(10):1311-5. PubMed ID: 19184123
[TBL] [Abstract][Full Text] [Related]
38. Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.
Gianni L; Munzone E; Capri G; Villani F; Spreafico C; Tarenzi E; Fulfaro F; Caraceni A; Martini C; Laffranchi A
J Natl Cancer Inst; 1995 Aug; 87(15):1169-75. PubMed ID: 7674322
[TBL] [Abstract][Full Text] [Related]
39. Characteristics of immediate hypersensitivity reaction to paclitaxel-based chemotherapy in gynecologic cancer patients.
Thangwonglers T; Santimaleeworagun W; Therasakvichya S; Saengsukkasemsak N; Pimsi P
Asian Pac J Allergy Immunol; 2023 Dec; 41(4):340-346. PubMed ID: 33068367
[TBL] [Abstract][Full Text] [Related]
40. Paclitaxel administered by 1-hour infusion. Preliminary results of a phase I/II trial comparing two schedules.
Hainsworth JD; Greco FA
Cancer; 1994 Aug; 74(4):1377-82. PubMed ID: 7914470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
